Calidad de vida en la enfermedad de Alzheimer. Cuestionario de Salud SF-36 / Quality of life in Alzheimer’s disease. SF-36 health survey

Objetivo. Evaluar la calidad de vida de pacientes con enfermedad de Alzheimer y relacionarla con el estado cognitivo y funcional. Método y pacientes. Se realizó la encuesta de calidad de vida SF-36, Versión Española 1.4, calculando la suma cruda de los resultados transformados en una escala 0-100 en las ocho dimensiones del test. Los pacientes fueron remitidos por neurólogos que trabajan de forma preferente en demencias en el área metropolitana de Valencia y poblaciones adyacentes, con diagnóstico de enfermedad de Alzheimer probable según los criterios del NINCDSADRDA. Se recogieron datos desde el punto de vista demográfico y social. Se realizó la escala de deterioro global, el Mini Mental State Examination (MMSE) y la fluencia verbal (FV). El estudio estadístico se realizó mediante la regresión lineal simple. Resultados. Se entrevistó a 111 pacientes, 35 hombres y 76 mujeres; la media de edad fue de 76 años. La media del MMSE fue de 12 puntos, y se relacionó con las dimensiones de función física, rol físico y el sumatorio de la salud física. La media de la FV fue de 5,1 animales, y se relacionó de forma significativa con las mismas dimensiones, la función social, el sumatorio de salud física y el sumatorio de salud mental. La media de la escala de deterioro global fue de 5 puntos y se relacionó con las mismas dimensiones que en la FV. Conclusiones. El deterioro cognitivo y la función en los pacientes con enfermedad de Alzheimer se relacionan con la mayoría de los aspectos de su calidad de vida (AU)

Objective. To evaluate quality of life in Alzheimer disease patients and its relationship with cognitive and functional status. Patients and methods. SF-36 health survey was perform to evaluate the quality of life in a sample of Alzheimer’s disease diagnosed cases, according to criteria established by the National Institute of Neurologic, Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association. Crude items summation were calculated from 0 to 100 in 8 tests dimensions. Demographic and social aspects were collect. The status of the global deterioration scale, a verbal fluency test and the Folstein Minimental test were determinated. Statistical analysis were conducted by means of simple lineal regression study. Results. 111 cases were analysed, 35 man and 76 women, the mean age was 76 years. The MMSE scale mean were 12 points, correlated with physic function, physic roll and physic health summary. Verbal fluency test mean was 5.1 animals, correlated with the same dimensions general health and mental health summary. And the general deterioration scale mean was 5, correlated with the same dimensions than Verbal Fluency test. Conclusions. Cognitive impairment and global deterioration function are correlated with some aspects of quality of life scales (AU)

Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.

Continuous subcutaneous apomorphine infusion (CSAI) is, at present, an alternative option for advanced Parkinson's disease (PD) with motor fluctuations. We studied the evolution of patients with PD and severe motor fluctuations long-term treated with CSAI. We reviewed data from 82 patients with PD (mean age, 67 +/- 11.07; disease duration, 14.39 +/- 5.7 years) and severe motor fluctuations referred to 35 tertiary hospitals in Spain. These patients were long-term treated (for at least 3 months) with CSAI and tolerated the procedure without serious side effects. We compared the baseline data of these 82 patients (before CSAI) with those obtained from the last follow-up visit of each patient. The mean follow-up of CSAI was 19.93 +/- 16.3 months. Mean daily dose of CSAI was 72.00 +/- 21.38 mg run over 14.05 +/- 1.81 hours. We found a statistically significant reduction in off-hours, according to self-scoring diaries (6.64 +/- 3.09 vs. 1.36 +/- 1.42 hours/day, P < 0.0001), total and motor UPDRS scores (P < 0.0001), dyskinesia severity (P < 0.0006), and equivalent dose of antiparkinsonian therapy (1,405 +/- 536.7 vs. 800.1 +/- 472.9 mg of levodopa equivalent units P < 0.0001). CSAI is an effective option for patients with PD and severe fluctuations, poorly controlled by conventional oral drug treatment.